Curia

Curia.jpg

Curia is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing of large and small molecules to pharmaceutical and biopharmaceutical customers. Curia's 3,700 employees at 30 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure.

CORPORATE

Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics.

To learn more visit us at curiaglobal.com

BIOLOGICS

Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics offering spans discovery to clinic and fill-finish services across monoclonal antibodies, recombinant proteins and mRNA therapeutics. Our scientific and process experts, and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics.

To learn more visit us at curiaglobal.com/biologics

SMALL MOLECULE

Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our small molecule offering spans discovery to commercial manufacturing and fill-finish services, integrating scientific, process, regulatory and analytical capabilities for API life cycle. Our combined state-of-the-art facilities, scalable technologies, and commitment to growth advances your program through drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com/research-development/

Related Resources

Fill-Finish Biologics

Fill-Finish Biologics

Content provided by Curia

White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion, while the blockbuster Keytruda could be the...